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1 INTRODUCTION  
 
1.1 Protein Misfolding Diseases  
The biological function of cells depends on the correct folding of a network of thousands protein. 
The information required to fold a protein into a functional, specific three-dimensional structure is 
contained in its amino-acid sequence. In general proteins fold properly into their native 
conformation. However, it’s possible that the protein adopts a wrong conformation, which keeps it 
from carrying out its function. This process is termed “Protein Misfolding”. Misfolding diseases 
comprise a group of disorders with dissimilar symptoms which can affect various organs and 
tissues. Nevertheless, they have the same underlying pathogenetic mechanism, namely an altered 
protein conformer with high β-sheet structure content. These conformational diseases include 
Alzheimer’s (AD), Huntington’s and Parkinson’s disorders, Prion-related Disorders (PrD), 
Systemic Amyloidosis, and Amyotrophic Lateral Sclerosis (Soto C., 2003) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Overview of the anatomical location of and macroscopic and microscopic changes characteristic of the 
neurodegenerative disorders. Note that the full neuropathological spectrum of these disorders is much more complex 
than depicted here. When there is more than one characteristic histopathological feature, these are depicted from left to 
right, as indicated in the labels listing microscopic changes (e.g., the 2 panels for AD depict an Aβ plaque [left] and 
neurofibrillary tangles [right]; Bertram, L. et al. J. Clin. Invest. 2005;115:1449-1457. 
 
Normally, the cell has a number of defense mechanisms to contrast the formation of misfolded 
proteins, as the system of chaperones, which induces re-folding, or the ubiquitin-proteasome system 
and the phagosome-lysosome system that limit the accumulation of misfolded proteins (Forman et 
al., 2004) (Figure 2). However, these control systems may well little against the pathological 
accumulation.  
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Fig. 2 Model of protein misfolding and fibrilization, leading to the deposition of aggregated protein in the 
nucleus, cytoplasm and extrecellular space. Genetic and environmental factors may accelerate this process, whereas 
cellular quality-control systems including molecular chaperones, the ubiquitin-proteasome system and the phagosome-
lysosome system limit the accumulation of misfolded proteins. 
 
The key event is a change in the secondary and tertiary structure of a normal protein without 
alteration in the primary structure. The unstable structural isoforms thus generated, in an attempt to 
seek lower energy levels and more stability, have a tendency to aggregate in ordered fibrils that are 
called amyloid. These fibrils, other than sharing cross β-structure, exhibit specific tinctorial 
properties such as iodine, Congo red and thioflavin-T have been used extensively for characterising 
the presence of amyloid fibrils and their rates of formation, both in tissue samples and, in an 
adapted method, in vitro (Klunk et al., 1989). Currently, there is no effective therapy for inhibiting 
or reversing protein aggregation and deposition in patients with protein misfolding diseases. 
However, the progress made in understanding the molecular basis of abnormal conformation has 
opened new perspectives for designing medications for these highly devastating disorders. In this 
context, growing evidence supports the notion that alterations in cholesterol homeostasis represent 
an additional feature shared by misfolding diseases, and that cholesterol may have a role in the 
formation of misfolded proteins (Mattson et al., 1999; Stefani et al., 2007).This is particularly 
apparent for AD and PrD in which abnormal cholesterol metabolism is frequently observed 
(Sjögren et al., 2006; Stefani et al., 2009). 
Although the precise nature of how cholesterol influences conformational transition has not yet 
been identified, studies exploring the effects of drugs interfering with cholesterol synthesis, 
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processing, and trafficking could be an evolving strategy for the identification of novel targets for 
the diagnosis, prevention and treatment of amyloidogenic disorders. 
 
1.2 Alzheimer’s Disease 
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease affecting 
millions of people worldwide. Multiple pathways have been implicated in AD pathogenesis, 
including neuronal cell death, oxidative damage, chronic inflammation, and protein aggregation 
(Govaerts et al., 2007; Giannakopoulos et al., 2009). Many years ago, silver and Congo-red stains 
have evidenced in the cortical regions of the brains of patients affected by AD, the presence of 
characteristic dark, irregular, thread-like structures often with a brownish material in the centre, 
which was called neuritic plaque. The central core was represented by amyloid substance, while the 
irregular, beaded linear structures by small dendrites and axons with degenerative changes 
(dystrophic neuritis). Around the plaque, various cell types including astrocytes and 
microglia/macrophages were found. Afterwards, it was discovered that the amyloid deposit 
consisted of a peptide of 4 kDa in a β-sheet conformation that was called β-amyloid (Aβ) (Selkoe et 
al., 2001), and that it was part of a 79 kDa transmembrane protein, the amyloid precursor protein 
(APP). It is now well known that APP is processed by three enzymes α, β and γ secretases (Nunan 
et al., 2000). These secretases cut APP in different sites, resulting in distinct peptide fragments that, 
depending on the involved secretases, may have physiological or pathological functions. α-
secretase, a member of the ADAM family of metalloproteases (ADAM10), cleaves APP generating 
a secreted ectodomain (sAPPα) and a shorter membrane- fragment (C83). After this initial 
cleavage, γ secretase, a multi-protein complex (i.e. PSEN-1, APH-1, PEN-2), cleaves C83 domain 
releasing a small fragment called AICAD. Since the AICAD fragment dissolves easily within the 
cells without producing plaques, the APP processing via α-secretase was called “non-
amyloidogenic pathway”. β-secretase, a membrane bound aspartyl protease, also called BACE1, 
cleaves APP in its luminal domain to generate a β-secreted ectodomain (sAPP β). The remaining 
10-kD β-cleaved carboxy-terminal fragment of APP (C99) is subsequently substrate for γ-secretase, 
which cleaves C99 to release fragments with 40 or 42 aa residues known as Aβ1-40 or Aβ1-42. 
These fragments do not dissolve in the cells, but move to the extracellular side of the neural 
membrane where they aggregate generating the senile plaques (Figure. 3). This is known as the 
amyloidogenic way of APP metabolism (Ehehalt et al., 2003). Generally Alzheimer disease and 
Prion diseases are included among rafts neurodegenerative diseases, since the aberrant proteolytic 
processing of PrP and A-Beta occur in these lipidic membrane domains. Therefore, it is most likely 
that alterations in the composition of lipid rafts can lead to a variety of disease of lipid metabolism. 
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Figura 3. Processing of the APP and Aß store. The mature garage APP is tried along two metabolic streets in 
competition between them: The street of α-secretasy pathway that produces APPα and C83 (left), and the street of the ß- 
secretasy pathway that produces sAPPβ and C99 (right). 
 
1.3 Prion Disorders 
 
Prion Disease (PrD) are invariably fatal neurodegenerative disordes that. include Kuru, Creutzfeldt-
Jakob disease (CJD), Gerstman-Straussler-Scheinker syndrome (GSS) and fatal familial insomnia in 
humans (Bate et al., 2004), scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in 
cattle, and encephalopathies in mink, cats, mule deer, elk and several exotic ungulates (Harris, 
1999). In human beings a sporadic (~85% of cases), genetic (~15%) or acquired through dietary or 
medical exposure to infected tissues (<1%), while in animals only the infectious origin has been 
identified. (Novakofshi et al., 2005). Nevertheless, the expression Transmissible Spongiform 
Encephalopathies (TSE) is now commonly used to indicate all prion diseases, both in humans and 
animals, regardless of their origin. The first description of a Transmissible spongiform 
encephalopathies (TSE), ovine scrapie, was published in the middle of the 18th century (Koster et 
al.; 2003). These diseases are rapidly progressive, fatal and untreatable neurodegenerative 
syndromes that are neuropathologically characterized by spongiform change (microcavitation of the 
brain), neuronal loss, glial activation and accumulation of an abnormal amyloidogenic protein. The 
clinical features of TSEs which consist of mental changes, ataxia, and loss of fine control of body 
homeostasis are due to massive loss of neuron function in the brain and are characteristic of many 
other fatal neurodegenerative diseases. A human TSE, Creutzfeldt-Jakob disease (CJD), was first 
described in older humans by Creutzfeldt (1920). In the early 1950s a group of scientists led by 
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Gadjusek recognised a disease, Kuru, in the fore tribe of New Guinea, which showed great 
similarities with scrapie and CJD. Other human transmissible spongiform encephalopathies 
occurring after the age of 40 are Gerstmann-Straüssler-Scheinker syndrome (GSS) and fatal familiar 
insomnia (FFI), which are associated with a ataxia and progressive dementia, as also Kuru and CJD. 
Since 1996, a new variant CJD (vCJD), which probably derives from the consumption of cattle 
neural tissues contaminated with the Bovine spongiform encephalopathy (BSE), has been identified 
in the United Kingdom, France, the Republic of Ireland, Hong Kong, Italy, the United States and 
Canada and is characterized by young age of onset, a stereotypical pattern of illness progression and 
distinctive neuropathological features (Forman et al.; 2004) (Table 1).  
 
Disease  
 
Host Mechanism of pathogenesis 
Kuru  
 
Fore people Infection through ritualistic  cannibalism 
iCJD  
 
Humans Infection from prion-contaminated HGH, dura mater grafts, etc. 
vCJD  
  
Humans Infection from bovine prions? 
FCJD 
 
Humans Germ-line mutations in PrP gene 
GSS 
 
Humans Germ-line mutations in PrP gene 
FFI  
 
Humans Germ-line mutation in PrP gene (D178N, M129) 
 
SCJD 
 
Humans Somatic mutation or spontaneous conversion of PrPC into PrPSc? 
FSI Humans Somatic mutation or spontaneous conversion of PrPC into PrPSc? 
 
Scrapie Sheep Infection in genetically susceptible sheep 
 
BSE Cattle Infection with prion-contaminated MBM 
 
TME Mink Infection with prions from sheep or cattle 
 
CWD 
 
Mule deer, elk Unknown 
FSE Cats Infection with prion-contaminated bovine tissues or MBM 
 
Exotic ungulate 
encephalopathy 
Greater kudu, nyala, oryx 
 
Infection with prion-contaminated MBM 
 
 
Table 1. The prion diseases. iCJD, iatrogenic CJD; vCJD, variant CJD; fCJD, familial CJD; sCJD, sporadic CJD; 
GSS, Gerstmann–Straussler–Sheinker disease; FFI, fatal familial insomnia; FSI, fatal sporadic  insomnia; BSE, bovine 
spongiform encephalopathy; TME, transmissible mink encephalopathy; CWD, chronic wasting disease; FSE, feline 
spongiform encephalopathy; HGH, human  growth hormone; MBM, meat and bone meal (Aguzzi et al., 2000). 
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For a long time it was believed that the source of infection of the TSEs was a virus of a viroid. 
However, purification and characterization studies showed the possibility of a proteinaceous nature 
of the TSE agent. These results were consolidated by further studies, which showed that the scrapie 
agent is resistant to procedures that destroy nucleic acids such as treatment with nucleases and UV 
radiation (Koster et al.; 2003). In 1982 Prusiner isolated a protease and heat-resistant protein from 
the brain of scrapie-infected hamsters. He termed it PrPsc (scrapie-associated prion protein) and 
proposed that PrPsc is identical with the infectious agent. Although the exact physical nature of the 
transmissible agent is still controversial, a very large body of experimental data supports the 
`protein only' hypothesis, first outlined in general terms by Griffith in 1967 and enunciated in its 
updated and detailed form by Prusiner. This theory proposes that the agent is devoid of nucleic acid 
and consists solely of an abnormal conformer of the cellular prion protein, PrPc. The exact 
mechanism of the conversion from the cellular PrPc to the infectious form PrPsc is still unknown. 
The "normal", cellular isoform of the prion protein has exactly the same amino acid sequence as the 
scrapie isoform, but it does have different characteristics: PrPc is a monomeric protein 
predominantly α-helical (42%) with little β-sheet structure (3%), which is soluble in so-called 
"soft" detergents and is sensitive to digestion with proteinase K (PK). In contrast, PrPsc is mostly β-
sheet (43%) with less α-helical structure (30%), which is insoluble, and the N-terminus (aa 90-231) 
is unusually resistant to PK digestion (Harris et al., 1999; Caughey et al., 1991) (Figure. 4). 
 
 
Figure.4. Features of PrPc and PrPsc. 
 
It has been proposed that a direct interaction between the correctly folded PrPc form and the 
infectious misfolded isoform (PrPsc) is required for the abnormal conformational transition 
(Campana et al., 2005; Prusiner et al., 1998). According to this theory (Figure 5), PrPsc would act 
as a template upon which molecules of PrPc refold into exogenous PrPsc molecules through a 
process facilitated by another, thus far unidentified, protein termed "protein X”. During prion 
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propagation, protein X appears to bind to the terminus of the normal protein structure, which 
acquires substantial β-sheet structure post-translationally (Legname et al., 2007). 
 
Figure. 5. Conversion of PrPc into PrPsc. 
 
PrPc is formed by a C-terminal half compact domain structure consisting of three α-helices and a 
two stranded anti-parallel β-sheet, and by less structured N terminal half (Donne et al., 1997). 
Within this N-terminal domain there are four copies of an octapeptide repeat sequence that bind 
copper ions. Within the centre, there is a highly conserved hydrophobic region (aa residues 106–
126) that, at least as an isolated peptide, has neurotoxic properties (Chiesa et al., 2001) (Figura 6). 
 
 
Figure 6. PrPC schematic rappresentation:In this scheme protein’s functional domines and the portion of the protein 
with a well known secondary structure are indicated. 
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So far, PrPsc represent the unique marker for the diagnosis (post-mortem) as well as the only 
known component of the infectious agent, being able of self-propagation by inducing structural 
conversion of the normal PrPc into a likeness of itself. No effective means for ante-mortem 
diagnosis or therapeutic interventions are presently available for TSEs. Besides other reasons, the 
development of efficacious prevention/therapeutic strategies are also hampered by the knowledge 
that the pathogenesis of the prion diseases is the result of a fine and complex interaction between 
the infectious agent and one or more genetic factors (Hsiao et al., 1989; Gabizon, et al., 1993). The 
complexity of this interaction is well documented in the ovine scrapie (Pocchiari, 1994), in which 
many polymorphic codons have been described to date in the PrP open-reading frame. However, 
only the mutations at codons at 136 (A→V), 154 (R→H) e 171 (Q→R o H) are associated with 
susceptibility/resistence to the disease. These mutations originate different alleles: VRQ, ARQ, 
AHQ, ARH, ARR and 15 different genotypes. Of these, VRQ and ARQ allele are associated with 
high scrapie susceptibility, while ARR allele is associated with resistance (Goldmann et al., 1994). 
Given that ovine scrapie is the most studied prion diseases that displays pathogenetic similarities 
with the human CJD, it represents an ideal experimental model to gain more information on the 
prion biology and its correlation with cholesterol metabolism. 
It was previously reported that. the formation of PrPsc is dependent upon the interaction of PrPc 
with specific, cholesterol-rich membrane microdomains, commonly called lipid rafts (Vey et al., 
1996; Naslavsky et al., 1997). Over the last few years a significant amount of genetic, biochemical, 
and pharmacological data highlighted cholesterol modifications associated with PrPsc biogenesis. 
(Bach et al., 2009; Sorensen et al., 2009; Hwang et al., 2009). Cholesterol, a well known critical 
regulator of membrane structure and raft function, was demonstrated to be essential for the cell-
surface localization of PrPc (Bate et al., 2004; Gilch et al., 2006) and now emerges as the most 
important factor involved in the formation of misfolded proteins. 
 
1.4 The Crucial Role of Cholesterol in Cell Physiology 
The cholesterol is a vital biological molecule in mammals. It is the starting material or an 
intermediate compound from which the body synthesizes bile acids, steroid hormones, and vitamin 
D, as well as a the major component of plasma membranes (PM). Except for specialized cells 
(i.e.hepatocytes and enterocytes etc.) all other mammalian cells generally require cholesterol for the 
proper functioning of their membranes. In PM, rather than diffusing freely within the phospholipid 
bilayer, cholesterol mainly interacts, through its hydroxyl group, with the amide group of saturated 
phospholipids (sphingomyelin and glycosphingolipids). These cholesterol-sphingolipid complexes 
occur in high concentration in the outer bilayer leaflet, forming tightly packed domains called lipid 
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rafts (London et al., 2002). Lipid rafts are dynamic highly ordered membrane microdomains 
enriched in cholesterol, sphingolipids and saturated phospholipids. Conversely, the PM areas rich in 
phosphatidylcholine, and other unsaturated glycerol-based phospholipids having lower cholesterol 
affinity, are considered cholesterol-poor regions; these tend to be less densely packed and form 
liquid-disordered regions outside the rafts (non-raft regions) (Ohvo-Rekila et al., 2002; Clejan et 
al., 1998). In the lipid rafts, longer and saturated fatty acid phospholipids move in synchrony with 
the phospholipids on the inner side of the membrane, while in the non-raft regions the unsaturated 
phospholipids on one side of the membrane move independently of those on the other (Schmitz et 
al., 1990; Ridgway et al., 1999). The high concentrations of cholesterol-bound longer and saturated 
fatty acid sphingolipid tails make rafts ideal for holding a number of non-transmembrane proteins 
(Lucero et al., 2004), which include i) glycosyl phosphatidyl inositol (GPI)- anchored proteins, such 
as PrPc, which is involved in PrD, ii) proteolytic enzymes, such as β and γ secretases, which are 
involved in AD, and iii) acylated proteins, such as tyrosine kinases of the Src family, which are 
involved in signal transduction (in the cytoplasmic side). Transmembrane integral proteins are 
generally excluded from rafts, and are principally found in the non-raft regions (Rouvinski et al., 
2003). Once the cell is activated, membrane rafts are believed to function as a concentrating 
platform for a variety of signal transduction molecules (Esler et al., 2001). During activation, many 
rafts would cluster, forming a larger platform, thus allowing functional proteins to concentrate and 
interact, likely with cytoplasmic signalling factors, such as small G proteins, that are recruited to the 
cytoplasmic face of rafts in response to clustering, thereby facilitating the initiation of signaling 
events. Importantly, this clustering is believed to be cholesterol dependent (Selkoe et al., 2001; De 
Strooper et al., 2000). Cholesterol is thought to serve as a spacer between the saturated fatty acid 
chains of the sphingolipids and to function as a glue keeping raft proteins assembled together 
(Simons et al., 2004). It seems that cholesterol acts as a molecular sorting machine capable of the 
space-temporal coordination of the segregation, processing, trafficking, and functioning of raft-
resident proteins. Given this, even minor changes in raft cholesterol may lead to dissociation of 
resident proteins, rendering them non-functional and thus contributing to a variety of diseases, 
including misfolding disorders. Fortunately, cells and organisms have developed extraordinarily 
sophisticated mechanisms for controlling lipid composition, and hence the properties of biological 
membranes. This control mainly consists in aligning cholesterol content with the demands imposed 
by cell metabolic requirements. 
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1.5 Metabolism and Intracellular Trafficking of Cholesterol 
Commonly cited that in non-specialized cells 75-85% of total cellular cholesterol is mainly in rafts, 
in the form of free cholesterol (FC), while 10-15% is in cytoplas-mic lipid droplets (LDs), in the 
form of cholesterol esters (CEs), and only 0.1-2% is in ER membranes (Figure. 7). In these cells, 
FC derives either from the internalization of low-density lipoprotein (LDL) via LDL receptors 
(LDL–R) localized in clathrin-coated pits of non-raft PM, or from endogenous biosynthesis in the 
ER via 3-hydroxy-3-methy-lglutaryl coenzyme reductase A (HMGCoA-R)., or both CEs are formed 
by the action of an ER resident enzyme, acyl-CoA: cholesterol acyltransferase (ACAT1), also 
known as sterol O-acyltransferase (SOAT1), encoded by the SOAT1 gene. It catalyzes the bond 
between the hydroxyl FC group and the long-chain fatty-acyl-coenzyme A carboxylic group (Dessi 
et al., 2004). A tightly controlled network of cellular signalling and lipid transfer systems 
orchestrates the functional compartmentalization of cholesterol within and between organellar 
membranes. Despite the fact that, under normal conditions, ER cholesterol levels are very low, it 
appears that ER membrane FC is essential for the correct regulation of cholesterol homeostatic 
machinery (Prinz W et al., 2002). When ER-FC increases, a cellular sensor, SCAP, a sterol-
regulatory-element-binding protein (SREBP)-cleavage-activating-protein is blocked. SCAP is 
necessary for the proteolytic activation of SREBP-2, a transcription factor that promotes the 
expression of genes involved in cholesterol synthesis (HMGCoA-R) and uptake (LDL-R). Thus, 
high ER-FC represses cholesterol synthesis and uptake, while allosterically activating ACAT1, 
which is responsible for cholesterol esterification. The resulting CEs are stored, along with 
triglycerides (TG), in LD cores, which serve as transient neutral lipid depots (Maxfield et al., 2005). 
Since an excess of CEs in LDs leads to foam-cell-like formation, the excess must be removed. The 
only way for LDs to get rid of CE excess is to re-hydrolyze them to FC through nCEH activation. 
FC is then recycled to the membranes by cholesterol-binding proteins (cav1 and cav2), where it can 
be delivered to extracellular high-density lipoproteins (HDL), via the ATP binding- cassette-sub-
family A-member 1 (ABCA-1) transporter (Albrecht et al., 2007), for efflux. On the other hand, 
when FC-ER decreases, the SREBP–SCAP complex exits the ER, and SREBP2 undergoes two 
proteolytic cleavages. These cleavages release the SREBP2 cytosolic domain, which moves into the 
nucleus, where it induces LDL-R and HMG-CoA-R transcription, thus activating cholesterol 
synthesis and uptake. Concurrently, ACAT1 activity is inhibited and that of nCEH is induced. By 
hydrolyzing CE back to FC and fatty acids, nCEH allows cholesterol to leave the LDs, providing a 
prompt source of FC to replenish raft domains (Figure. 7). 
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Figure 7. Compartmentalization and key homeostatic molecules of cellular cholesterol. 
 
In this scenario the cholesterol ester cycle emerges as the principal short-term protection to keep 
PM cholesterol within a range in harmony with cell metabolic needs. 
 
1.6 Cholesterol Homeostasis in the brain 
The mammalian nervous system contains a disproportionate amount of cholesterol. In the brain the 
cholesterol content is about 10-fold greater than in any other organ (Dietschy et al., 2004) 
indicating that cholesterol plays a central role in the development and maintenance of the brain and 
nervous system. Within the brain some 70% of cholesterol is present in myelin, where it fulfils a 
critical insulating role. It is likely that the requirement for efficient signalling despite a small 
transverse diameter of axons was a key selective pressure driving the accretion of cholesterol in the 
mammalian brain (Snipe et al., 1997). At a cellular level the myelin sheath consists of sections of 
plasma membrane repeatedly wrapped around an axon, with the extrusion of virtually all of the 
cytoplasm. Myelin is formed by two very specialized cells: the oligodendrocyte in CNS and the 
Schwann cell in the peripheral nervous system.  
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The remaining 30% of brain cholesterol is divided between glial cells (20%) and neurons (10%). 
According to various in vitro studies with cultured cells, astrocytes synthesize at least 2-3 fold more 
cholesterol than neurons, while oligodendrocytes have an even higher capacity for cholesterol 
synthesis, at least during periods of active myelination. (Bjorkhem et al., 2004). It is noteworthy 
that even minor changes in the structure of the constituent sterols of the nervous system, e.g. the 
presence of one additional double bond, leads to a change in the biophysical properties of the cell 
membrane with profound clinical effects. The strategy used by nature for cholesterol homeostasis in 
the brain and spinal cord is different from that in other parts of the body. Due to the efficient blood-
brain barrier there is no passage of lipoprotein-bound cholesterol from the circulation to the brain 
(Dietschy et al., 2004). The blood-brain barrier thus prevents diffusion of large molecules at the 
level of tight junctional attachments between adjacent capillary endothelial cells. In addition to this, 
there is also no trans vesicular movement of solution across the capillaries. It is possible that one or 
more members of the ATP binding cassette transporter superfamily may be involved in the 
exclusion of circulating cholesterol from the brain, but conclusive evidence is lacking for this. Thus 
all the cholesterol present in the brain is formed by de novo synthesis and the same is true also for 
the cholesterol in the peripheral nervous system. Except for the active phase of specific pathological 
conditions, almost all (at least 99%) cholesterol in the nervous system is unesterified. In the adult 
brain most of its synthesis is balanced by formation of a hydroxylated metabolite, 24S-
hydroxycholesterol (24S-OHC), which is able to pass across the blood-brain barrier and enter the 
circulation and it represents one of the most important mechanism for the elimination of brain-
derived cholesterol (Bjorkhem et al., 2001; Russell et al., 2009). In addition to this there is a small 
efflux of cholesterol from the brain in the form of apolipoprotein E (APOE) containing lipoproteins 
via the cerebrospinal fluid (Pitas et al., 1987). The turnover of the cholesterol present in membranes 
of the neuronal cells and in astrocytes may however change in response to different factors. Under 
normal conditions cholesterol 24-hydroxylase (CYP46A1), the enzyme system responsible for 
formation of 24S-OHC is only present in neuronal cells, with particularly high levels in the 
pyramidal neurons in various layers of the cortex, in the hippocampus and in Purkinje cells in the 
cerebellum (Russell et al., 2009). 
The uptake of cholesterol by these cells may thus be balanced by the secretion of 24S-OHC. The 
24S-OHC secreted from the neuronal cells may be of importance for regulation of cholesterol 
synthesis and secretion of this cholesterol in APOE-bound form astroglia. In contrast, cholesterol 
synthesis appears to be regulated by similar mechanisms both outside and inside the brain with 
hydroxy-methylglutaryl CoenzymeA reductase (HMGCR) being the most important regulatory 
enzyme (Dietschy et al., 2004). 
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Although formation of 24S-OHC is responsible for the removal of about two-thirds of cholesterol 
from the brain, under normal conditions APOE seems to be the most important carrier of cholesterol 
in the brain extracellular fluid. Therefore, in the brain, where the turnover of cholesterol is much 
slower than in other tissues, neuronal cells, in contrast to other cell types, require a constant supply 
of. lipid molecules. The mammals have developed complex and sophisticated homeostatic 
mechanisms that function to maintain cellular cholesterol levels in membranes within a narrow 
range. Alterations and/or disturbances in these homeostatic mechanisms, either by genetic, 
environmental, diet-induced or natural aging can lead to altered cell function that probably result in 
greater susceptibility to aberrant processes and /or lower responsiveness to repair mechanisms. 
 
1.7 Cholesterol and Protein Misfolding 
Growing evidence indicates that rafts are involved in amyloid generation from APP and PrPc, 
possibly through the creation of a favourable lipid environment. It has been reported that, when 
APP and PrPc molecules occupy a lipid raft region of the membrane, they are more accessible to 
and, thus, preferentially cleaved by, amyloidogenic enzymes (i.e. raft resident β-secretase). On the 
other hand, when APP and PrPc molecules are outside rafts, they appear to be preferentially cleaved 
by non-amyloidogenic non-raft resident α-secretase (ADAM 10) (Allinson et al., 2003). 
The most straightforward interpretation of this information is that APP and PrPc are present in two 
cellular pools: one, outside rafts, where these two proteins are processed in a normal way; the other, 
inside the rafts, where abnormal cleavage takes place [(Ehehalt et al., 2003; Harris et al., 1999). 
Interestingly, very recent results (Sarnataro et al., 2009) include evidence that PrPc is found in non-
raft regions, besides being present, as GPI-anchored protein, in rafts. These authors also reported 
that, in neuronal cells, PrPc translocates out of rafts, upon copper binding to the N-terminal 
octapeptide repeats, prior to being endocytosized through clathrin-coated pits. This membrane 
compartmen-talization model would explain how the same protein may be processed in two 
different and mutually exclusive ways. Interestingly, the amount of cholesterol associated with 
these domains exerts profound effects on the functions of the raft-resident proteins. It has been 
claimed that two alternative and opposite scenarios involving disturbance of the cholesterol-rich raft 
domains describe the role of cholesterol in PrPsc generation. The high membrane cholesterol model 
implies that cholesterol enrichment would favor contact between PrP and misfolded PrPsc isoforms, 
by triggering the raft-clustering process. The low membrane cholesterol model claims, instead, that 
undesired amyloidogenic protein-protein interactions are favoured by raft disassembly caused by 
cholesterol depletion (Simons et al 2002). 
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Constant low levels of cholesterol in lipid rafts could lead to a continuous stimulus of cell growth 
promotion (Wang et al., 2005), or induce cellular prion protein PrPc to undergo pathologic 
processes (Figure 10) leading to the generation of their corresponding pathogenic forms (Simons et 
al., 2001; Diomede et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure10. The PrPC to PrPSc conversion in membrane rafts (“Raft clustering”). 
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2. THE PRESENT INVESTIGATION: 
 
It is now well established that cellular cholesterol metabolism plays an important role in PrPsc 
generation. In the last decade, several lines of evidence indicated that prion disorders are likely 
associated with lipid metabolic alterations that involve an increase in the cellular cholesterol pool. 
In this respect, in our laboratory, during the period of my internship for Degree in Biology and the 
post-lauream training period, we investigated the role of cholesterol in the pathogenesis of prion 
diseases, and obtained evidences of an abnormal accumulation of CE in brains, as well as in ex vivo 
peripheral blood mononuclear cells (PBMCs) and skin fibroblast cultures, from scrapie-affected 
with respect to healthy sheep. Compared to sheep carrying a scrapie-resistant genotype, increased 
CE pool was also found in tissue and cell samples from sheep carrying a scrapie-susceptible 
genotype (Pani et al., Cholesterol Metabolism in Brain and Skin Fibroblasts from Sarda Breed 
Sheep With Scrapie-resistant and Scrapie-susceptible Genotypes, Am. J. Infec. Dis., 2007, 3, 143-
150; Pani et al., Accumulation of Cholesterol Esters in ex vivo Lymphocytes from Scrapie-
susceptible Sheep and in Scrapie-infected Mouse Neuroblastoma Cell Lines, Am. J. Infec. Dis., 
2007, 3, 165-168). Similar CE alterations were also observed in mouse neuroblastoma N2a cell 
lines persistently infected with mouse-adapted 22L and RML strains of mouse-adapted scrapie 
(Pani et al., Accumulation of Cholesterol Esters in ex vivo Lymphocytes from Scrapie-susceptible 
Sheep and in Scrapie-infected Mouse Neuroblastoma Cell Lines, Am. J. Infec. Dis., 2007, 3, 165-
168). The treatment of ex vivo PBMCs and skin fibroblasts from scrapie-affected sheep with a 
number of drugs known to interfere with different steps of cholesterol metabolism strongly reduced 
the accumulation of CE. In the infected N2a cells, these cholesterol modulators were able to parallel 
CE reduction to a selective inhibition of the scrapie-like prion protein (PrPres), indicating a direct 
effect of cholesterol alteration on the misfolding of PrP. This was supported by the finding that 
PrPres-producing cell populations of subclones from scrapie-infected cell lines were characterized 
by higher CE levels than clone populations not producing PrPres. 
Overall, the results obtained in our previous studies suggested that abnormal cholesterol 
esterification could indicate an altered metabolic cholesterol arrangement that predispose the cell to 
the development of pathological processes involving abnormal activation, processing, and/or 
trafficking of membrane resident proteins. If this was true, then cholesterol homeostasis restoration 
and in particular the inhibition of cholesterol esterification may represent a nove approach for the 
control of prion diseases. On these premises, during my PhD, I have continued the studies on the 
role of cholesterol in the pathogenesis of prion disorders. For clarity sake, description of the whole 
body of data embedded in this thesis can be subdivided into three different sections. The first one is 
on the major faced aspect, that is “Studies on the role of cholesterol in the pathogenesis of prion 
 20 
disorders”(Chapter I). Specific objectives were to evaluate i) gene and protein expression of ACAT-
1, Cav-1, and PrPc in brains and skin fibroblasts from scrapie-affected and scrapie-susceptible 
sheep; ii) the lipid content in cultured scrapie-infected mouse neuroblastoma cell lines, as well as in 
rodents experimentally infected with scrapie, by different colorimetric and analytical method; iii) 
the changes in cellular cholesterol pools following treatment with drugs, both in single and dual-
drug associations, targeting different steps of the cholesterol metabolism leading to cholesterol 
esterification (i.e. everolimus, pioglitazone, sandoz 58035, progesterone, verapamil, and others) , 
and to cholesterol neosynthesis (i.e. pravastatine). The second part of my studies were focused on 
the characterization of the soluble prion infectivity from scrapie-affected hamster brains (Chapter 
II). The last part of my researches was devoted to investigate the potential superantigen activity of 
Alzheimer’s peptides (i.e. sAPPα, Aβ40 and Aβ42) (Chapter III).  
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2.1 CHAPTER I 
 
STUDIES ON THE ROLE OF CHOLESTEROL IN THE PATHOGENESIS OF PRION DISORDERS 
 
2.1.1 ACAT-1, Cav-1 and PrP expression in scrapie susceptible and resistant sheep (Article I) 
 
As above mentioned, our previous studies on the role of cholesterol homeostasis in the pathogenesis 
of Scrapie, revealed abnormal accumulation of CE in the brains and in ex vivo PBMCs and skin 
fibroblast cultures from healthy and scrapie-affected sheep carrying a scrapie-susceptible genotype, 
with respect to samples from sheep with a resistant genotype. In this work we showed that 
intracellular accumulation of cholesterol esters (CE) in fibroblasts cultures derived from scrapie-
susceptible sheep was accompanied by parallel alterations in the expression level of acyl-
coenzymeA: cholesterol-acyltransferase (ACAT1) and caveolin-1 (Cav-1), that are respectively 
involved in the pathways leading to intracellular cholesterol esterification and trafficking. 
Comparative analysis of cellular prion protein (PrPc) mRNA, showed an higher expression level in 
cells from animals carrying a susceptible genotype, with or without Scrapie. These data suggest that 
CE accumulation in peripheral cells, together with the altered expression of some proteins involved 
in intracellular cholesterol homeostasis, might serve to identify a distinctive lipid metabolic profile 
associated with increased susceptibility to develop prion disease following infection. 
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2.1.2 In vitro synergistic anti-prion effect of cholesterol ester modulators in combination with 
chlorpromazine and quinacrine (Article II) 
 
Our previous studies also showed that a number of drugs which inhibit cholesterol esterification by 
targeting different steps of cholesterol metabolism/trafficking were able to reduce CE levels in both 
PBMCs and skin fibroblasts isolated from scrapie-affected sheep, and to determine a parallel 
inhibition of PrPres in prion infected 22L-N2a cell lines. In the article below, in these prion-infected 
cell lines, we reported increased anti-prion activity of dual-drug combinations consisting of 
cholesterol ester modulators associated with prion inhibitors. In these experiments, the synergistic 
activity was obtained with the cholesterol ester modulators everolimus, pioglitazone, progesterone, 
and verapamil associated with the anti-prion chlorpromazine, and with everolimus and pioglitazone 
associated with the anti-prion quinacrine. In addition, comparative lipid analyses in prion-infected 
vs. uninfected N2a cells by different lipid probes (Oil red O; Nile red and filippin), lipid separation 
techniques (TLC), and lipid precursors (labelled actetate and oleate), demonstrated a general 
derangement of type and distribution of the cholesterol ester (CE), free cholesterol (FC), and 
triglyceride pools in the infected cells. Single-drug treatments differently affected synthesis of the 
various lipid forms, whereas combined drug treatments appeared to restore a lipid profile similar to 
that of the untreated-uninfected cells. We concluded that anti-prion synergistic effects of cholesterol 
ester modulators associated with the cholesterol-interfering anti-prion drugs chlorpromazine and 
quinacrine, may arise from the ability of combined drugs to re-establish lipid homeostasis in the 
prion-infected cells. Overall, these data suggest that inhibition of prion replication can be readily 
potentiated by combinatorial drug treatments, and that steps of cholesterol/cholesterol ester 
metabolism may represent suitable targets. 
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2.1.3 Pharmacologic Cholesterol Homeostasis Affects Prion Generation in a Synergistic 
Manner (Article III) 
 
In this article we discuss all previous results pointing to a direct link between systemic metabolic 
lipid alterations and the pathogenesis of prion diseases. At the cellular level, our findings indicate 
that prion infection/replication is likely associated with a lipid environment that involve changes 
both in the content and distribution of the different pools of cellular cholesterol, as well as of other 
cellular lipids, including phospholipids and triglycerides. The synergic anti-prion effect showed by 
drug combinations affecting cholesterol metabolism at different levels suggest that pharmacologic 
interventions restoring lipid homeostasis may represent a more successful therapeutic approach than 
drug treatments lowering cholesterol content. Notably, our data also point to neutral lipid 
accumulation in peripheral cells as an easy-to-detect hallmark associated with disease and/or 
indicative of increased susceptibility to develop disease following infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article III 
 
 49 
 
 
 
 
 
 
 
 50 
 
 
 
 
 
 
 
 51 
 
 
 
 
 
 
 
 52 
 
 
 
 
 
 
 
 53 
 
 
 
 
 
 
 
 54 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
 
 
 56 
2.1.4 Comparative analysis of the variation of cholesterol in prion-infected N2a cells and in 
scrapie-affected mouse brains (Manuscript) 
 
2.1.4.1 Introduction 
 
Although our findings are in line with those by others that associated prion infections with altered 
cholesterol content, there is still no general agreement on the intracellular cholesterol forms (FC and 
CE) affected by prion infection. Contrasting results in the literature may be due not only to the 
complexity of prion biology, but also to intrinsic limitations of the diverse methods for cholesterol 
measurements in the various samples.  
 
2.1.4.1.a Methods for Measuring Cholesterol in tissues. 
Because of the broad involvement of cholesterol in normal and pathophysiological processes in the 
nervous system, its quantification under different conditions is critical to understand cholesterol role 
in the brain function. Methods to determine the cholesterol content of various cellular compartments 
are subjected to technical limitations. So far, several methods for measuring lipid in brain tissues 
have been used. Earlier cholesterol tissues staining techniques were based on chemical reactions 
such as the Schultz reaction, Lieberman-Burchard reaction, or reaction with fluoric–chloride–
sulphuric acid and perchloric acid (Cossec et al., 2010). Currently, the methods for measuring lipids 
in brain tissues can be classified into two groups: non enzymatic methods and enzymatic methods. 
The enzymatic methods are direct assays amenable to automated procedures, suitable for the rapid 
and direct automated analysis of cholesterol using a limited amount of sample, and have largely 
replaced the more laborious non-enzymatic methods in clinical laboratories. In the enzymatic assay, 
cholesteryl esters are hydrolyzed by cholesterol esterase into fatty acid and free cholesterol; the 
latter is then oxidized by cholesterol oxidase (CO) to yield the corresponding ketone and hydrogen 
peroxide coproducts. Thus, the enzymatic methods for assaying cholesterol are based on the 
measurement of H2O2 by way of horseradish peroxidase (HRP)-coupled oxidation of H2O2 sensitive 
probes (Drake et al., 1999). By these technique, CE are not direcly determined.  
In contrast, the non enzymatic methods are time-consuming multiple-step assays, and require the 
use of corrosive chemicals. These methods include colorimetric and fluorescent probes that allow 
visualization of cholesterol in tissues. Filipin is the most widely used fluorescent probe for 
visualizing free cholesterol (FC) because it binds with high affinity to the 3β-hydroxyl group of 
cholesterol (Rudolf and Curcio, 2009). Enzymatic and colorimetric methods are limited by the rapid 
bleaching of filipin under confocal microscopy, and the lack of specificity of both fillipin and 
cholesterol oxidase staining, respectively (Lebouvier et al., 2009).  
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Several other methods involve i) preliminary column chromatography of the total lipid into three or 
more fractions, which are then analyzed separately (Privett et al., 1971); ii) three or more solvent 
systems for TLC (Downing et al., 1968; Pernes et al., 1980); iii) a chemical pre-treatment of the 
TLC plate; iv) HPLC lipid separation with ultraviolet light, fluorescence, or mass spectrometric 
detection, and gas chromatography with mass spectrometric or flame ionization detection, which 
altogether represent the most selective and sensitive technicques for lipid studies (Cossec et al., 
2010). 
 
2.1.4.1.b Targeting Cholesterol to Prevent Protein Misfolding 
With respect to cholesterol metabolism as potential therapeutic target in prion diseases, in our 
studies suggested that cell treatments with various cholesterol interfering drugs, as cholesterol ester 
inhibitor everolimus, the cholesterol-trafficking modulators progesterone and verapamil, and 
pioglitazone, a drug which induces the cell redistribution of free fatty acids, in combination with 
prions inhibitors, as the lysosomotropic drugs quinacrine and chlorpromazine, which, in addition to 
several other effects, respectively determine cell cholesterol redistribution and activation of 
cholesterol biosynthesis, transportation and efflux, showed synergic anti-prion effects, apparently 
by restoring cholesterol homeostasis in infected cells. Other authors, however, found an inhibition 
of prion infection by using FC-lowering drugs (i.e. statins) in both in vitro (Taraboulos et al., 1995; 
Bate et a., 2004), and in vivo (Mok et al., 2006) prion models. A number of studies, in fact, have 
revealed that cholesterol-lowering drugs prevent prion replication in vitro, presumably by 
redistribution of PrPc out of the rafts (Taraboulos et al., 1995), while other studies produced 
evidence that cholesterol depletion abolishes PrP-raft association, promotes its accumulation and 
increases substantially its misfolding. After more than a decade of investigations in cell-based and 
in vivo models of PD, no conclusive and unequivocal answer is yet available. The promising early 
studies on the anti-amyloidogenic activity of cholesterol biosynthesis inhibitors, statins, and on their 
beneficial effects in experimental rodent Scrapie, have been followed by studies producing mixed 
results and inconclusive information on the statins’ mode of action in vivo (Table 2). 
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Table 2. Effect of Cholesterol-Interfering Drugs in AD and PrD Models. 
 
 
 
Statins act as reversible competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, the key rate-controlling enzyme in cholesterol biosynthesis, that catalyzes the 
conversion of HMG-CoA to mevalonic acid. They are pharmacologically categorized as lipophilic 
(e.g. Lovastatin, Simvastatin) or hydrophilic (e.g.Pravastatin) compounds, depending upon their 
solubility in lipid solvents or water (Schachter, 2004). Lipophilic statins, as Simvastatin, are 
commonly considered able to cross promptly the blood-brain barrier (BBB) by passive diffusion. 
However, it was shown in rodents that hydrophilic statins, such as Pravastatin (PRV), may enter 
hepatic cells (Nezasa et al., 2003; Evers & Chu, 2008) as well as brain capillary endothelial cells at 
BBB (Kikuki et al., 2004; Cheng et al., 2005) via an ATP dependent anion transport polypeptidic 
system (Oatps). These transporters, expressed in a variety of different tissues, including gut, kidney 
and brain, play important roles in drug absorption, distribution and excretion (Seithel et al., 2008; 
Kivisto & Niemi, 2007). In cell-prion systems, different statins proved to be selective inhibitors of 
the scrapie-like prion protein (PrPres), indicating that in vitro statin anti-prion activity is linked to 
their lowering of cellular cholesterol levels (Taraboulos et al., 1995; Bate et a., 2004). 
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However, in vivo studies in rodent scrapie models showed that statins delayed disease progression, 
and prolonged survival time (Mok et al., 2006; Kempster al., 2006; Vetrugno et al., 2009) through 
pleiotropic neuroprotective effects (Bate et al., 2007; Haviv et al., 2008), rather than by lowering 
brain cholesterol levels.Therefore, in spite of the increasing data in literature the clinic utility of 
drugs affecting cholesterol neosynthesis, in prion disorders, is being re-examined. Moreover, many 
aspects of the mechanisms that link cholesterol homeostasis alterations and pathologic conversion 
of prion protein yet remain unclear, probably also due to the lack of sensitive and specific methods 
for assessing cholesterol levels in the brain at subcellular resolution. 
 
During my PhD, in the ambit of the “Master and Back program” of the Sardegna region, I carried 
out a research intership at the “Istituto Superiore di Sanità”, Department of “Clinica, Diagnostica e 
Terapia delle Malattie Neurodegenerative del Sistema Nervoso Centrale”, directed by Professor 
Maurizio Pocchiari. Recently, Pocchiari’s research group showed delayed disease symptoms and 
prolonged survival times of 139A strain scrapie-infected mice treated orally with Pravastatin (PRV) 
(Vetrugno et al., Oral pravastatin prolongs survival time of scrapie infected mice. Journal of 
General Virology, 2009, 90, 1775–1780, DOI 10.1099/vir.0.009936-0). On these premises, I 
investigated the cholesterol metabolism alterations in an in vivo murine model of prion infection, by 
comparative analysis of the total, free and cholesterol esters content with two different methods for 
measuring cholesterol in tissue (by enzymatic and non-enzymatic method), in Normal C57BL mice 
vs terminally ill C57BL/6 mice inoculated with the 139A scrapie strain, and in brains from 
terminally ill C57BL/6 Pravastatin-treated mice inoculated with the 139A scrapie strain. 
 
Therefore, the purpose of this study was 1) to compare the cholesterol analysis in N2a cell line vs 
22L-N2a scrapie-infected and uninfected vs scrapie infected mice by Fluorometric and HPLC-MS 
method; 2) to evaluate the cholesterol content in infected untreated vs scrapie infected Pravastain-
treated mice. As expected, HPLC anlysis has shown advantages for its high selectivity, its high 
sensitivity, and its potential for simultaneous quantification for several lipid classes. In present 
study, the lipid analysis showed that neuronal cultures and mouse brains prion-infected, were 
characterized by an altered cholesterol metabolic profile associated with increased of TC, FC and a 
higher CE pool, confirm our previous evidence of a relationship between abnormal accumulation of 
cholesterol esters and cell susceptibility to scrapie infection/replication. Treatment with cholesterol 
synthesis inhibitor Pravastatin slightly reduced the cholesterol free content but no total cholesterol 
content in brain homogenates of scrapie infected mice. 
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Our findings seems to indicate that brain cholesterol alterations during PrD involve dynamic 
modifications in cholesterol homeostatic networks. These data confirm our hypothesis that steps of 
cholesterol/cholesterol ester metabolism may represent suitable targets of potential clinical 
importance. 
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2.1.5 GENERAL CONCLUSIONS OF THE STUDIES ON CHOLESTEROL CHANGES IN PRION 
INFECTION 
 
In conclusion, our studies on the role of cholesterol in the pathogenesis of prion disorders in 
different in vitro, ex vivo, and in vivo models, highlighted the presence of metabolic lipid alterations 
associated with prion infection, involving changes in the content and distribution of the different 
pools of cellular cholesterol (i.e. free cholesterol and cholesterol esters), as well as of other cellular 
lipids, including phospholipids and triglycerides. Higher CE pool was observed in brains and skin 
fibroblasts of healthy sheep with a scrapie susceptible prion genotype compared to sheep carrying a 
scrapie-resistant prion genotype, opening the possibility of a link between cellular prion 
polymorphism(s) and cholesterol homeostasis regulation. In addition, we showed increased ACAT1 
expression in skin fibroblasts from scrapie-affected and scrapie-susceptible sheep. In prion- infected 
N2a cells, we found increased content and altered distribution of FC, TG, phospholipids and CE, 
which were not organized in LDs. In the infected N2a cultures, analysis of the CE-Fatty acid 
composition showed, with the only exception of Arachidonate, an increase of the amounts of each 
fatty acid of the CE-FA fraction. In addition, N2a cell treatments with combinations of various 
cholesterol interfering drugs showed synergic anti-prion effects, apparently by restoring cholesterol 
homeostasis in the prion- infected cells. In our hands, in agreement with the results in in vitro and 
ex vivo prion models, we have shown that also prion-affected mouse brains were characterized by 
an altered cholesterol metabolic profile associated with increased TC, FC and CE levels, and that 
pravastatin treatment determined significative reduction of the free cholesterol, an increase of the 
cholesterol ester, while total cholesterol remained unchanged.  
On the basis of these data, we propose a mechanism by which cholesterol may influence protein 
misfolding and amyloid generation (Figura 11). It is well known that cells are normally protected 
from the accumulation of potentially toxic FC excess by ACAT-1–mediated esterification and by 
cholesterol efflux. Stored CE do not usually exceed the nCEH capacity to re-hydrolize CE to FC 
and to recycle FC back to PM. In the brain, excess FC is then converted to the efflux form of 
cholesterol (24S-hydroxy-cholesterol) that cross BBB and enter the blood stream. Therefore, failure 
of one or more of these homeostatic mechanisms, possibly caused by genetic and/or environmental 
factors, may be responsible for the altered cholesterol distribution found in protein misfolding- 
affected cells. One consequence of this is a slowing of the transportation of cellular FC to the PM 
that, over time, may lead to lipid raft disassembly. These events may favour interaction between 
PrPc and PrPsc, inducing structural conversion of the normal PrPc into amyloidogenic PrPsc, which 
is widely reported to trigger pathological events. 
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Figure. 11. Proposed cholesterol network modifications influencing protein misfolding and amyloid generation. 
 
According to this model, the use of multitarget therapeutic strategies, aimed at re-establishing right 
cholesterol amounts and their differential distribution in PM microdomains, could represent a more 
successful approach than monotherapy-based treatments for the prevention/treatment of misfolding 
disorders. 
 
2.1.6 FUTURE OBJECTIVES 
I will compare the quali-quantitative analysis of intracellular lipids (by HPLC and NMR) in the 
various models (sheep brains and N2a cells), either untreated and treated with modulators of 
esterification (i.e. everolimus), both alone and in combination one with another, as well as with 
chlorpromazine and quinacrine. 
In addition to these studies, I will focus on the evaluation and characterization lipid alterations that 
are related to different polymorphisms of the prion protein and likely associated to progression of 
infection (pre-clinical, initial and terminal illness stage) by NMR and TLC analysis, both in the 
CNS and in peripheral cells, in a natural model of prion disease such as scrapie in sheep that is 
endemic in our Region.  
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2.2 CHAPTER II 
 
STUDY OF SOLUBLE INFECTIVITY FROM SCRAPIE-INFECTED HAMSTER BRAIN 
 
2.2.1 INTRODUCTION 
 
Despite TSEs (transmissible spongiform encephalopathies), such as CJD (Creutzfeldt–Jakob 
disease), are relatively rare but have received much attention in recent years because of the potential 
number of individuals in the U.K. affected following the epidemic of BSE (bovine spongiform 
encephalopathy). A major issue of current concerns is that blood donors may be subclinically 
infected with the BSE agent and could potentially transmit variant CJD through blood transfusion to 
healthy individuals. (Llewelyn et al., 2004; Peden et al., 2004). 
Currently, efforts are directed, on one side, toward the development of tests capable of detecting 
infectivity in asymptomatic individuals (i.e. PMCA, QUIC), and on the other, toward the 
development procedures (e.g, leucodepletion; nanofiltration; depth filtrations; chromatography; 
NaPTA, trichloroacetic acid , polyanions precipitation), able to remove or inactivate prions from 
blood components or plasmaderived products with brain fractions of transmissible spongiform 
encephalopathy (TSE)-infected rodents as spiking materials. These spiking materials (e.g.,brain 
homogenates, microsomal fraction, caveolae-like domains, purified PrPsc), however, are loaded 
with pathological prion protein (PrP TSE) aggregates that are likely not associated with blood 
infectivity. The presence of these aggregates may invalidate these studies. In this contest, recently, 
Pocchiari’s research group has developed a simple and fast method to prepare a soluble infectious 
material, containing small amounts of PrPTSE from hamster brains infected with the scrapie strain 
263k (V. Berardi, F Cardone ., Valanzano A., Lu M, Pocchiari M., Transfusion, 2006). This 
fraction, called SHS (high speed supernatant), is virtually free from PrPTSE in aggregate form and 
contains only small amounts of PrPTSE in soluble form. In this regard, the SHS fraction can 
therefore be an excellent material for endogenous spiking of human blood in validation experiments 
aimed at demonstrating procedures to remove or inactivate TSE infectious agents. 
 
On these premises, the experimental activity during the first year of my PhD, in the Department of 
Clinica, Diagnostica e Terapia delle Malattie Neurodegenerative del Sistema Nervoso 
Centrale”(ISS, Rome) directed by Professor Maurizio Pocchiari, was focused on the studies on 
characterization of the infectivity soluble from scrapie-adapted hamster’s brain homogenates. 
I compared two different extraction methods to precipitate the PrP pathological: streptomycin 
extraction method and ultracentrifugation in the presence of denaturing detergent Sarkosyl. 
Subsequently, to evaluate the presence of PK-sensitive isoform in the SHS fraction, the SHS 
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fraction was subjected to digestion with thermolysin, a thermostable neutral metalloproteinase 
enzyme, which
 
preserve both PK-sensitive and PK-resistant isoforms of disease related PrP. In 
addition, I have also acquired experience in the handlling of highly infectious brain tissue in a 
containment facility of class III; in the biochemical methods utilised for the purification and 
characterization of PrPres from affected tissues; and with the histological techniques aimed to 
verify the amount and distribution of neurological injury in affected individuals. Finally, I have 
gained experience on procedures relaying: animal restraint; intraperitoneal anesthesia, and 
intracerebral inoculation with brain homogenates experimentally infected with scrapie; sampling of 
the major organs within the accumulation of pathogenic prion protein. 
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2.2.2 MATERIALS AND METHODS 
 
2.2.2.1 Preparation of 263K brain homogenates 
Scrapie-adapted (i.e. 263K prion) hamsters brain tissues were homogenized in nine volumes (10% 
w/v) of lysis buffer (100 mM NaCl, 10 mM EDTA, 0.5%, Nonidet P40, 0.5% w/v sodium 
deoxycholate, 10 mM Tris HCl, pH 7.4) and then brain homogenates were dispersed by sonication 
pulses (Vibra Cell, Sonics & Materials Inc., Newtown, CT) while kept on ice. Scrapie-adapted 
hamster’s brain homogenates were clarified at 1000 × g for 10 minutes at 4°C ( ). The supernatants 
were used as PrPSc stock sample for deposition on SDS-PAGE. 
 
2.2.2.2 Western blot measurement by ECL chemiluminescence detection 
The supernatant were thawed and treated for 60 minutes at 37 ° C with proteinase K (PK; Sigma 
Chemical Co., St. Louis, MO) at a final enzyme concentration of 50 µ g per mL. The digestion was 
stopped by adding protease inhibitors (Complete, Roche Diagnostics GmbH Roche Applied 
Science, Mannheim, Germany) in accordance with the manufacturer’s instruction. After PK 
treatment, the samples were serially diluted in half-log steps in NuPAGE gel loading buffer, boiled 
for 10 minutes in a water bath, and electrophoresed on 12 percent NuPAGE Bis-Tris gels 
(Invitrogen Corp., Carlsbad, CA) for 60 minutes at 125 V. The nitrocellulose membrane (Hybond 
ECL, Amersham Biosciences Europe GmbH, Freiburg, Germany) was soaked in Towbin transfer 
buffer for 5 minutes before “sandwich” assembly and semidry transfer for 60 minutes at 125 mA at 
4 ° C. The membrane was blocked for 60 minutes at 37 ° C in 5 percent nonfat dry milk (Bio-Rad, 
Hercules, CA), dissolved in Tris-buffered saline (pH 8) with 0.05 percent Tween 20 (TBST), and 
incubated overnight at 4 ° C with 3F4 monoclonal anti-hamster 27- to 30-kDa fragment of protease-
resistant prion protein (PrP 27-30 ) antibody 16 (provided by H. Diringer) diluted 1:1000 in TBST. 
The membrane was rinsed with TBST (five changes of solution in 25 min), incubated for 120 
minutes at 37°C with an HRP antimouse (Amersham) diluted at 1:3000 in TBST, and rinsed again. 
Bands were revealed by the ECL chemiluminescence detection kit (Santa Cruz) andrecorded onto 
sensitive films (Hyperfilm ECL, Amersham) 
 
2.2.2.3 Western blot measurement by CDP-star chemiluminescence detection 
The supernatant were thawed and treated for 60 minutes at 37 ° C with proteinase K (PK; Sigma 
Chemical Co., St. Louis, MO) at a final enzyme concentration of 50 µg per mL. The digestion was 
stopped by adding protease inhibitors (Complete, Roche Diagnostics GmbH Roche Applied 
Science, Mannheim, Germany) in accordance with the manufacturer’s instruction. Sodium dodecyl 
sulfate–polyacrylamide gel electrophoreses and Western blot assays were performed according to 
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Lee and coworkers 15 with some modifications. After PK treatment, the samples were serially 
diluted in half-log steps in NuPAGE gel loading buffer, boiled for 10 minutes in a water bath, and 
electrophoresed on 12 percent NuPAGE Bis-Tris gels (Invitrogen Corp., Carlsbad, CA) for 60 
minutes at 125 V. The nitrocellulose membrane (Hybond ECL, Amersham Biosciences Europe 
GmbH, Freiburg, Germany) was soaked in Towbin transfer buffer for 5 minutes before “sandwich” 
assembly and semidry transfer for 60 minutes at 125 mA at 4 ° C. The membrane was blocked for 
60 minutes at 37 ° C in 3 percent nonfat dry milk (Bio-Rad, Hercules, CA), dissolved in Tris-
buffered saline (pH 8) with 0.05 percent Tween 20 (TBST), and incubated overnight at 4 ° C with 
3F4 monoclonal anti-hamster 27- to 30-kDa fragment of protease-resistant prion protein (PrP 27-30 
) antibody 16 (provided by H. Diringer) diluted 1:2000 in TBST. The membrane was rinsed with 
TBST (five changes of solution in 25 min), incubated for 90 minutes at room temperature with an 
alkaline phosphatase–labeled goat antimouse IgG (Perkin-Elmer Sciences, Wellesley, MA) diluted 
at 1:5000 in TBST, and rinsed again. Bands were revealed by the CDP-star chemiluminescence 
detection kit (Applied Biosystems, Foster City, CA) andrecorded onto sensitive films (Hyperfilm 
ECL, Amersham) 
 
2.2.2.4 Extraction of PrPres by Streptomycin precipitation method 
Scrapie-adapted hamster’s brain homogenates were treated for 60 minutes at 37 ° C with proteinase 
K (PK; Sigma Chemical Co., St. Louis, MO) at a final enzyme concentration of 80-100 µg/mL. The 
digestion was stopped by adding protease inhibitors (Complete, Roche Diagnostics GmbH Roche 
Applied Science, Mannheim, Germany) in accordance with the manufacturer’s instruction. The 
samples were then incubated for 1 h at 37°C in presence of 0.7 M of streptomycin (Sigma) and were 
centrifuged at 12000 g for five minutes at room temperature. The supernatants were carefully 
discarded and the pellets were resuspended in 50% v/v 8 M urea and 2X sample loading buffer 
(SDS 4%, mercaptoethanol 2%, glycine 192 mM Tris 25mM and 5% sucrose denaturing buffer). 
After vigorously vortex stirring for five minutes the preparations were heated at 100°C for ten 
minutes. The supernatants that corresponded to re-solubilized materials from pellets were gathered 
by centrifugation at 10000 g for five minutes and used as PrPSc stock sample for deposition on SDS-
PAGE. 
 
2.2.2.5 Extraction of PrPres by Sarkosyl ultracentrifugation method 
Scrapie-adapted hamster’s brain homogenates were treated for 60 minutes at 37 ° C with proteinase 
K (PK; Sigma Chemical Co., St. Louis, MO) at a final enzyme concentration of 80-100 µg/mL. The 
digestion was stopped by adding protease inhibitors (Complete, Roche Diagnostics GmbH Roche 
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Applied Science, Mannheim, Germany) in accordance with the manufacturer’s instruction. The PK 
treated samples were incubated with 10% sarkosyl at 30% for 15 minutes at room temperature and  
ultracentrifugated at 100000 rpm for 2 h at 20°C. The supernatants were carefully discarded and the 
pellets were resuspended in 2X sample loading buffer (SDS 4%, mercaptoethanol 2%, glycine 192 
mM Tris 25mM and 5% sucrose denaturing buffer). After the preparations were heated at 100°C for 
ten minutes. The supernatants that corresponded to re-solubilized materials from pellets were 
gathered by centrifugation at 12000 rpm for five minutes at room temperature and used as PrPSc 
stock sample for deposition on SDS-PAGE. 
 
2.2.2.6 Extraction of water-soluble scrapie infectivity (SHS) 
263K scrapie–infected hamster brains were suspended in 9 vol of sterile phosphate-buffered saline 
(PBS; pH 7.4) and homogenized by use of a Teflon-glass Potter tissue 
grinder. The homogenate was dispersed with 10 sonication pulses (Vibra Cell, Sonics & Materials 
Inc., Newtown, CT) while kept on ice and then centrifuged at 825 × g for 15 minutes at 25 ° C (GS-
6R, rotor GH-3.7, Beckman Coulter, Fullerton, CA). Low speed supernatant (S LS ) was sonicated 
as above and ultracentrifuged at 220,000 × g for 30 minutes at 25 ° C (Optima TL-100, rotor TLA 
100.3, Beckman Coulter, Fullerton, CA). This highspeed supernatant (S HS ) was collected and the 
highspeed pellet (P HS) was sonicated in sterile PBS to obtain a 10 percent suspension (gram-
equivalents of brain/PBS). These three fractions (S LS , S HS , and P HS ) were stored at− 70° C 
until assayed. 
 
2.2.2.7 Extraction of PrPres in SHS fraction by Streptomycin precipitation method 
This highspeed supernatant (SHS) was collected from 263K scrapie–infected hamster brains as 
desribed above. Subsequently, SHS fraction was treated for 60 minutes at 37 ° C with proteinase K 
(PK; Sigma Chemical Co., St. Louis, MO) at a final enzyme concentration of 50 µg/mL. The 
digestion was stopped by adding protease inhibitors (Complete, Roche Diagnostics GmbH Roche 
Applied Science, Mannheim, Germany) in accordance with the manufacturer’s instruction. The 
samples were then incubated for 1 h at 37°C in presence of 0.7 M of streptomycin (Sigma) and were 
centrifuged at 12000 g for five minutes at room temperature. The supernatants were carefully 
discarded and the pellets were resuspended in 50% v/v 8 M urea and 2X sample loading buffer 
(SDS 4%, mercaptoethanol 2%, glycine 192 mM Tris 25mM and 5% sucrose denaturing buffer). 
After vigorously vortex stirring for five minutes the preparations were heated at 100°C for ten 
minutes.  
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The supernatants that corresponded to re-solubilized materials from pellets were gathered by 
centrifugation at 10000 g for five minutes and used as PrPSc stock sample for deposition on SDS-
PAGE. 
 
2.2.2.8 Detection of PK-sensitive disease-related prion protein with Thermolysin 
SLS and SHS fraction from 263K scrapie–infected hamster brains were treated for 30 minutes at 70 
° C with Thermolysin at a final enzyme concentration of 20 and 10 µg/mL respectively. The 
digestion was stopped by adding EDTA 2 mM. After Thermolysin treatment, the samples were 
serially diluted in half-log steps in NuPAGE gel loading buffer, boiled for 10 minutes in a water 
bath. PK-resistant and PK-sensitive disease-related prion protein isoforms were detected by 
Western blot procedure with CDP-star chemiluminescence detection as previously described.  
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2.2.3 RESULTS AND DISCUSSION 
At present it is not possible to have a definite ante-mortem diagnosis for prion encephalopathies, 
nor there are therapies that can cure or halt the progression of these disorders. In this respect prion 
disorders are not dissimilar from other neurodegenerative disease, yet the possibility to study highly 
reliable, non enginereed, animal models confers to prion disorders a primary role in the fight against 
the growing threat posed by neurodegenerative diseases. In the prion field, the possibility to 
formulate an early diagnosis before the appearance of clinical symptoms is essential in order to 
identify infectious carriers and also to start a therapeutic treatment before the appearance of clinical 
symptoms and permanent neuronal damage. Currently protease-resistant disease-associated prion 
protein is the best-known biological marker for TSEs, and the demonstration of PrPsc in human or 
animal tissues is essential to formulate a definite diagnosis of TSE. One important limitation to this 
approach is the sensitivity of the detection system: amounts of PrPsc high enough to be revealed by 
conventional methods are only present in the brain at the relatively late stage of the disease, 
whereas, animal transmission studies clearly demonstrated that infectivity replication starts during 
the early stage of the incubation period and gradually increases as the disease progresses. 
During my internship at the Istituto Superiore di Sanità, I learned all the operative procedures 
recommended by the World Health Organization to work with the infectious agents responsible for 
Transmissible Spongiform Encephalopathies (World Health Organization Infection control 
guidelines for transmissible spongiform encephalopathies, Report of a WHO consultation, Geneva 
Switzerland, 23-26 March 1999; WHO/CDs/CSR/APH/2000.3), and the detailed procedures of the 
WHO laboratory manual (WHO laboratory biosafety manual, Third edition, WHO press, Geneva, 
Switzerland, 2004) to work with class III pathogens in a BSL III facility.  
The acquisition of this know-how was the basis for the realization of the experiments described in 
the rest of this paragraph. Recently, Moussa et al. (2006) published that streptomycin sulphate is 
able to combine and selectively precipitate PrPsc from brain homogenates. It is likely that 
electrostatic interaction occurs between guanidine and/or ammonium groups of streptomycin 
sulphate and amino acids residues selectively exposed by pathological PrP. When PrP molecules are 
cross-linked by streptomycin, reticulation develops, leading to the formation of flocculated 
aggregates in liquid solutions. These authors claim that this new and selective extraction procedure 
may help to produce fast and reliable diagnosis from infected tissues. Based on these results, I 
decided to evaluate the reliability and the sensitivity of this precipitation method in brain 
homogenates from hamsters infected with scrapie strain 263K.  
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I also compared the yield of PrPsc recovery by the streptomycin extraction method to that of an 
alternative protocol based on ultracentrifugation steps in the presence of the non-denaturing 
detergent sarkosyl (Figure 12).  
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Figure 12: Comparisons of PrPres detection by streptomycin extraction method and sarkosyl ultracentrifugation 
method. 
 
I found that starting from identical amounts of brain tissue, the streptomycin extraction mehod yield 
a western blot signal that is three times higher than the sarkosyl-based extraction method (Figure. 
12). However, the latter protocol allows to obtain a final fraction that contains a lower amount of 
contaminants which translate into the possibility to load a higher amount of sample in each well, 
thus giving a higher sensitivity than the streptomycin extraction mehod.  
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Figure 13: PrPres (263K) by immunoblotting ECL chemioluminascence detection system (esposition over night). 
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Figure 14:PrPres (263K) by immunoblotting CDP-star chemioluminascence detection system (esposition over night). 
 
In the second part of my work on the development of an optimized method for the identification of 
PrPsc, I set up and compared two different systems to detect the prion protein by immunoblotting: 
ECL chemiluminescence detection system (Figure. 13) and CDP-star chemiluminescence detection 
system (Figure. 14) in brain homogenates from scrapie-infected (strain 263K) hamsters. I found that 
the CDP-star chemiluminescence detection system allows to demonstrate the presence of PrPsc in 
0.1 micrograms of brain tissue whereas the ECL system can only identify the presence of PrPsc in 1 
microgram of tissue. This translates into a difference of about one order of magnitude.With the aim 
to assess the sensitivity and specificity of the secondary antibody, I have also executed a screening 
of different anti-mouse IgG Alkaline Phosphatase antibodies produced in goat (data no snown). 
The optimized procedures described above are been then applied to studies on the characterization 
of infectivity soluble from scrapie-adapted hamster’s brain homogenates. 
Recently the Pocchiari’s research group has developed a simple and fast method to prepare a 
soluble infectious material (called SHS), containing small amounts of PrPTSE from hamster brains 
infected with scrapie strain 263k. (Berardi et al., 2006). This fraction, called SHS (high speed 
supernatant), is virtually free from PrPTSE in aggregate form and contains only small amounts of 
PrPTSE in soluble form and can therefore be an excellent material for studies on the 
characterization of the infecting agent and for experiments aimed at removing and inactivation of 
the infectious agent of TSEs. My research goal was to characterize the infectivity soluble from 
scrapie-adapted hamster’s brain homogenates. This procedure involves homogenization of hamster 
brains in 9 volumes of phosphate buffer, followed by centrifugation at low speed, and by 
ultracentrifugation at high speed. In order to measure the PrPTSE in SHS fraction, I treated the SHS 
fraction with streptomycin, a molecule capable of binding and selectively precipitate PrP 
pathological, creating an electrostatic interaction between the guanidine and/or group of 
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streptomycin sulfate ammonium itself and amino acids residues, selectively exposed by the 
pathological PrP (Moussa et al., 2006; Leclere et al., 2008).  
The SHS analysis by Western blot shown that the streptomycin is unable to precipitate the 
infectivity in the SHS fraction. Subsequently, to characterize SHS fraction, I submitted the SHS to 
digestion with proteinase K, assaying the enzyme at different concentrations, to detect the presence 
of pathological PrP isoforms sensitive to digestion with this enzyme (Owen et al., 2007), which 
commonly used in both diagnostic and research to remove PrP cell and identify the pathological 
PrP. PK-treatment shown that, at low concentrations of PK tested, the electrophoretic pattern of 
PrPTSE was slightly different respect to uninfected controls (Figure15). 
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Figure 15: Detection of proteinase K-sensitive desease –related prion protein in SHS after streptomycin precipitation. 
 
The result therefore not excluded the presence of pathological PrP isoforms sensitive to digestion 
with proteinase K. In a subsequent experiment, I submitted the SHS digestion with thermolysin, a 
proteolytic enzyme that degrades efficiently PrPc, preserving both the pathological isoform of PrP 
resistant to digestion with proteinase K, and those susceptible (Cronier et al., 2008). Digestion was 
performed varying some experimental parameters (temperature, pH and incubation time) to identify 
the optimum conditions for efficiently removes the PrPc, leaving PrPTSE in its entire length. I 
founded that the PrPTSE produced under these experimental conditions shown a modest reduction 
in signal intensity compared to that obtained with the standard protocol of digestion with proteinase 
K (Figure 16), this suggested that PrP pathological in the SHS fraction is formed by isoforms 
resistant to digestion with proteinase K.  
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Figure 16: Detection of proteinase K-sensitive desease –related prion protein with Thermolysin. 
 
 
2.2.4 CONCLUSIONS
Overall, our data suggested that the streptomycin extraction method yield a 
higher western blot signal that the sarkosyl-based extraction method in 263k scrapie-infected 
hamster brain homogenates. However, this antibiotic is unable to precipitate the infectivity in SHS 
fraction. Probably the infectivity in the SHS fraction is associated with dimmers or small aggregates 
of PrPTSE. In addition the SHS digestion with thermolysin, that preserving both PK-sensitive and 
PK-resistant isoforms of disease related PrP, showed a modest reduction in signal intensity 
compared to that obtained with the standard protocol of digestion with proteinase K. This result 
seems to exclude the presence of PK-sensitive isoform in the SHS fraction and suggests that PrP 
pathological contained within the SHS fraction is formed by isoforms resistant to digestion with 
proteinase K. 
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2.3 CHAPTER III 
NEUROINFLAMMATION IN ALZHEIMER DISEASE: ALZHEIMER’S PEPTIDES BEHAVE 
AS SUPERANTIGENS?  
 
2.3.1 INTRODUCTION  
2.3.1.a Neuroinflammation in Alzheimer’s Disease 
In many chronic neurodegenerative diseases, including disease Alzheimer's and prion disorders, the 
role of neuroinflammation correlated with the presence of misfolded proteins in the System Central 
nervous (CNS) has been analyzed. In these conditions, glial cells (astrocytes, microglia and 
oligodendrocytes) are described as "activated", a term used to indicate their morphological change 
relative to their resting state, which is accompanied by a number of over-expression of antigens on 
their cell surface or in cytoplasm. The activation of glia, although by mechanisms not fully clarified 
yet, is the first defense mechanism against the pathological abnormalities that occurs in 
neurodegenerative diseases (Farfara et al., 2008). The most characteristic inflammation associated 
with chronic disease and neurodegenerative disorder is well documented in Alzheimer’s disease ( 
McGeer et al., 2002). Recent studies have shown that close association between deposits of 
amyloidogenic Aβ peptide and microglial cells, can have a role in the development of Alzheimer's 
disease, by activating immune response and inflammatory cytokines and chemokines production 
(Hashioka et al., 2009). Activated microglia are associated with Aβ fibrils in AD brain samples, and 
may interact with infiltrated T cells to induce inflammation. (Akiyama et al., 2000).  
To limit undesiderable and dangerous auto-immune effects, the brain evolved to limit access of the 
immune system. This limitation is mediated by mechanisms such as the physical blood-brain barrier 
and a molecular milieu that suppresses immune function (Moalem et al., 1999; Aloisi et al., 2001). 
The CNS is thus often described as “immune privileged.” However, a body of evidence suggests 
that T cells normally, although to a limited extent, survey the CNS (Hickey et al., 1991; Aloisi et 
al., 1993). This ability of T cells to cross the blood-brain barrier has primarily been described for 
activated cells that survey the organs of the body during an immune response. To elicit T cell 
activation in the CNS, an Ag must be phagocytized and processed by local APCs. The professional 
APCs of the CNS are the parenchymal microglia and the perivascular cells. The parenchymal 
microglia have recently been characterized as myeloid progenitors cells that can differentiate into 
macrophage-like or dendritic-like cells (Fischer et al., 2001; Santambrogio et al., 2001). 
Differentiation of microglia and its effect on T cell activation may relate to brain pathology, such as 
that induced by amyloid β-peptide in Alzheimer’s disease.  
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Aβ peptides induce in fact microglia and astrocytes activation, and are actually recognized as Ag 
that must be removed. If microglia and astrocyte activities are not able to eliminate the Ag-Aβ 
complexes, this response may become chronic and neurotoxic (Monsonego et al., 2003). 
 
2.3.1.b Studies on Alzheimer’s peptides as potential superantigens 
In the last two decades it has become apparent that Aβ plaques are associated with inflammatory 
mediators and adhesion molecules, and that neurons re-express cell cycle proteins during AD 
pathogenesis. The presence in neocortical areas of clusters of activated microglia in classic plaques 
is consistent with a neurological form of low grade chronic inflammation (Akiyama et al., 2000). 
Moreover, studies on the alteration systemic of cholesterol homeostasis in peripheral cells of AD 
patients by some collegues that collaborate with my group, had revealed increased proliferation in 
PBMCs from AD patients compared to those from healthy donors. Based on these observations, we 
investigated whether the AD peptides, sAPPα, Aβ40 and Aβ42 act as superantigens being able to 
activate a non-specific response of all T cell. The antigenic molecules with superantigen activity are 
able to induce an abnormal non-specific activation of T-cells resulting in polyclonal T cell 
activation leading to massive cytokines release. Examples of superantigens are exotoxins SEB and 
SPE-C produced by Gram-positive bacteria Staphylococcus aureus and Streptococcus pyogenes, 
respectively (Fraser & Proft, 2008).  
Superantigens bind to the variable portions of MHC-II of the APC and the T-cell Receptor (TCR) of 
helper T-cell (Th), but in a way different from the physiologic antigen-receptor binding. The 
interaction with MHC-II usually occurs in the variable region of α chain (Alouf et al., 2003) and 
more rarely in the β-chain variable region (Mehindate et al., 1995); this link makes the correct 
placement of the molecule for interaction with the variable β chain of TCR. A common antigen is 
able to activate approximately 0.001-0.0001% of total T cells in the body, while superantigens are 
able to activate up to 20% of the total (Li et al., 1998). The polyclonal activation is due to the 
extreme affinity of superantigens for TCR. This non-specific response leads to release of massive 
amounts of cytokines involved in inflammation, including IL-1, IL-2, IL-6, TNF-α, IFN-γ, MIP-1α 
and β (macrophage inflammatory protein 1α and 1β) and MCP-1 (monocyte chemoattractant protein 
1) (Stiles et al., 2005). The massive systemic release of cytokine, that normally are produced and 
acted locally, especially TNF-α, may lead to SIRS (systemic inflammatory response syndrome), or 
toxic shock, a condition of very severe systemic inflammation that can rapidly lead to coma and 
death. Therefore, a better understanding of the interactions between T cells and amyloidogenic 
peptides could help to identify mechanisms underlying a atypical inflammatory response, and reveal 
new targets to modulate inflammation in the brain of AD patients. 
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2.3.2 MATERIALS AND METHODS 
 
2.3.2.1 Isolation of human lymphocytes from peripheral blood  
Blood samples were centrifuged at 2200 rpm for 15 minutes, the buffy coat was collected and 
PBMCs were isolated by density gradient centrifugation (lymphoprep, density 1.077 g / L; 
Nycomed Pharma) at 1200 rpm for 10 minutes at 20 ° C. and washed twice with Hanks balanced 
salt solution (HBSS). The PBMCs purified, were seeded onto 24-well plates at a density of 1 x 104 
cells / mL in RPMI 1640 medium with the standard supplements: (10% fetal calf serum (FCS), 200 
mM L-glutamine, and 100 U/mL penicillin-streptomycin) and growth-stimulated with 10 µg/ml 
phytohemagglutinin (PHA; Sigma) for 24, 48 and 72 hours. The trypan blue exclusion test was used 
to assess cell viability. These freshly isolated (ex vivo) PBMCs were utilized for the experiments: 
proliferation assays with labeled thymidine, MTT , Oil red O staining of neutral lipids and 
aggregation assay. 
 
2.3.2.2 Proliferation Assay of PBMCs treated with AD-peptides by [3H]-TdR incorporation 
For [3H]-Thymidine-incorporation studies, the cells were seeded onto 24-well plates at a density of 
2 x 106 cells/mL, in RPMI supplemented with 10% FBS, 1% antibiotic and 1% glutamine. All 
proteins PHA, sAPPα, Aβ40 and Aβ42 were added to cultures at a final concentration of 1 mg/well. 
An equal volume of PBS without Ca2 + and Mg2 + was added to controls. At 24 and 48 hours after 
seeding, cells were incubated in duplicate for 24 h with [3H]-thymidine (3 µCi/well). After 
incubation, the cells were rinsed twice with phosphate buffered saline (PBS), and DNA was 
precipitated by adding 10% trichloroacetic acid at 4°C for 30 minutes. Cells were digested with 0,1 
M NaOH at room temperature. Aliquots were harvesting and counting to determinate the [3H]-
thymidine radioactivity content on a β-scintillation counter. 
 
2.3.2.3 Proliferation Assay of PBMCs treated with AD-peptides by MTT method 
The cells were seeded onto 96-well plates, at the density of 2 x 106 cells/mL, in RPMI 
supplemented with 10% FBS, 1% antibiotic and 1%  glutamine. All proteins, PHA, sAPPα, Aβ40 
and Aβ42 were added to cultures at a final concentration of 1 mg/well. An equal volume of PBS 
without Ca2+ and Mg2+ was added to controls. After 48 and 72 hours incubations, cell proliferation 
was determined, by the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) 
(Sigma,Italy) method.  
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Yellow MTT was reduced to purple formazan in the mitochondria of living cells. The absorbance of 
this colored solution was quantified after 4 days by measuring at a wavelength 570 nm by a 
spectrophotometer. 
 
2.3.2.4 Staining of neutral lipids of lymphocytes treated with AD-peptides  
The cells were seeded onto 12-well plates at the density of 2 x 106 cells/, in RPMI supplemented 
with 10% FBS, 1% antibiotic and 1% glutamine. All proteins, PHA, sAPPα, Aβ40  and Aβ42 were 
added to cultures at a final concentration of 1 mg/well. An equal volume of PBS without Ca2+ and 
Mg2+ was added to controls. After 48 hours incubation, cells were centrifuged twice at 1600 rpm 
for 3 minutes to remove any medium residual. Pellet was suspended in 50 µL of PBS and the cell 
suspension was seeded onto 12-well plates for Oil red O staining. The cells were fixed by soaking 
in 10% formalin and then treated with isopropyl alcohol (60%), washed, and stained with oil red O 
(ORO) (a lipid-soluble
 
dye which stains NL, including CE, but not FC). They appear as bright red 
spots in the cytoplasm, and are then counterstained with Mayer's hematoxylin. After staining, cells 
were imaged using a Leitz inverted-phase microscope fitted with a digital camera. At least two 
different fields per sample were imaged and analyzed.
 
 
2.3.2.5 Aggregation Assay of LG-2 Cells 
 
Healthy Lymphoblastoid cells LG-2 (a kind gift of John D. Fraser, University of Auckland, New 
Zealand) were seeded onto two 96-well plates respectively at the density of 5 x 105 cells/mL and 1 
x 105 cells/mL in RPMI supplemented with 10% FBS, 1% antibiotic and 1% glutamine. Cells in 
duplicate wells were stimulated by the addition of peptide, sAPPα Aβ40 and Aβ42. All proteins 
were added at two different concentrations 0.1g/well and 1g/well. An equal volume of PBS without 
Ca2+ and Mg2+ was added to controls. Cells were incubated at 37° C for 24 hours and cell clusters 
were counted and photographed under by light microscopy every hour.  
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2.3.3 RESULTS  
 
2.3.3.1 Effect of AD-peptides on clusters formation of B lymphocytes  
To assess the ability of sAPPα, Aβ40 and Aβ42 peptides to activate B-cells, which express MHC-II 
molecules, we used the LG-2 cell aggregation assay. These cells when exposed to the presence of 
superantigen toxins, have the tendency to aggregate, forming typical clusters. To assess the 
experimental conditions suitable for the aggregation assay, cells were seeded at two different 
density and treated with two different concentrations of peptides. Respect to control, as shown in 
Figure 17, cells seeded at the density of 1 x 104 cells/mL and treated with the proteins at the 
concentration of 0.1 g /well, showed no significant differences in the clusters formation at 90 
minutes after addition of peptides. While after 24 hours incubation, cells treated with both sAPPα 
and Aβ40, at the concentration of 1 g/well, showed some clusters. Cells incubated with both 
concentrations of Aβ42 used, showed typical aggregates which, although consisting of few cells, 
appeared more regular and more compact. 
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Figure 17
. 
Aggregation assay of B lymphocytes (1 x 104 LG-2 cells/mL)
 
untreated versus treated with AD-peptides. 
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The cells seeded at higher density and treated with sAPPα and Aβ40 peptides, at the concentration 
of 0.1 and 1 µg/well after 30 minutes of incubation, showed no visible differences compared to 
untreated controls. Peptide Aβ42-treatment, after 30 and 90 minutes, induced the formation of more 
aggregates at both concentrations tested (Figure. 18). 
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Figure 18. Aggregation assay of B lymphocytes (5 x 104 LG-2 cells/mL) untreated versus treated with AD-peptides. 
 
2.3.3.2 Effect of AD-peptides on clusters formation of T lymphocytes 
To assess the ability of proteins to act as superantigens and bind directly to TCR of T lymphocytes, 
without being processed by the cells expressing MHC-II molecules, we used the T lymphocytes cell 
aggregation assay. Cells were photographed after 72 hours the addition of peptides, sAPPα, Aβ40 
and Aβ42 at a concentration of 0.2 µg/well. The mitogen PHA was used as positive control. Cells 
treated with sAPPα appeared slightly aggregated, respect to lymphocytes treated with PHA, which 
showed several clusters, index cellular activation (Figure. 19). Cells treated with peptides Aβ40 and 
Aβ42, showed abnormal distribution similar to monolayer accompanied by the presence of cells 
similar to blasts. 
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Figure 19. Aggregation assay of T lymphocytes untreated versus treated with AD-peptides. 
 
2.3.3.3 Content of neutral lipids in normal human lymphocytes treated with AD-peptides 
To verify the activation status of lymphocytes treated with the protein in study, we stained the cells 
with Oil red O. Figure 20 shows neutral lipid staining of healthy lymphocytes treated with PHA, 
sAPPα, Aβ40 and Aβ42. As expected lymphocytes stimulated with PHA seemed all colored red, 
indicating their activation status. While cells treated with sAPPα showed no significant differences 
to untreated control. Lymphocytes incubated with Aβ40 and Aβ42 seemed red, dead and atrophic; 
this result was more evident in cells treated with Aβ42.
 
 
PBMC + PHA
PBMC + sAPP PBMC + Aβ40 PBMC + Aβ42
PBMC-Control
 
 
Figure 20. Oil Red O stained of T lymphocytes untreated versus treated with AD-peptides. 
PBMC-Control PBMC-PHA72 PBMC-sAPP(0.2ug) 
PBMC-Aβ40 (0.2ug) PBMC-Aβ42 (0.2ug) 
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2.3.3.4 Proliferation assay in normal human lymphocytes treated with AD-peptides  
To assess the ability of proteins, sAPPα, Aβ40 and Aβ42, to stimulate the T lymphocytes 
proliferation , two assays were performed in parallel, [3H]-thymidine proliferation assay and the 
MTT assay. Through the incorporation assay with [3H]-thymidine was quantified the DNA 
synthesis of normal lymphocytes stimulated both with PHA, the non- amyloidogenic peptide sAPPα 
and amyloidogenic peptides Aβ40 and Aβ42. DNA synthesis was measured 48 and 72 hours after 
the addition of proteins. With respect to controls, as shown in Figure 21, cells treated with PHA 
showed an increase of DNA synthesis after 48 hours by adding of mitogen, with a further increase 
to 72 hours. While the cells treated both with sAPPα, Aβ40 and Aβ42 showed no significantly 
differences in DNA synthesis, compared to control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. DNA synthesis of lymphocytes treated with AD-peptides by [3H]-thymidine incorporation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Cells viability of lymphocytes treated with AD-peptides by MTT assay .
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Although assays performed with nucleotides labeled with radioactive isotopes are considered 
among the most sensitive for measuring DNA synthesis, we used also another method, the MTT 
assay, which is widely used to assess cell viability and activity screening, especially for its easy 
implementation and speed of response. As shown in Figure 22, cell viability in lymphocytes treated 
with PHA, sAPPα Aβ40 and Aβ42 peptides by MTT methods confirming the results obtained by 
[3H]-thymidine incorporation assay. In conclusion, these results showed no significantly increase in 
the cell proliferation induced by the AD peptides, with both assays used. These results indicated 
that at the times considered, both the non-amyloidogenic fragment sAPPα and amyloidogenic 
peptides Aβ40 and Aβ42 do not act as superantigens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
3.3.4 DISCUSSION 
 
In the studies carried out to evaluate the ability of AD peptides to act as superantigens, LG-2 cell 
aggregation assay showed a slight difference in cells incubated with the amyloidogenic Aβ42 
peptide, while showed no significant differences was seen in cells incubated with sAPPα and Aβ42 
peptides. Although proliferation assays in human lymphocytes showed no significantly differences 
in the proliferation of cells exposed to AD peptides, the aggregation assay showed abnormal, 
epitelial-like morphology, accompanied by blast-like enlargment of cell size of T lymphocytes. 
More information were obtained by Oil red O staining of T lymphocytes. Noteworthy is the fact 
that cells incubated with Aβ40 and Aβ42 peptides, especially those treated with Aβ42, showed 
more intensive stain, although apparently atrophic cells, confirming the data in the literature of a 
higher toxicity of the Aβ42 than Aβ40 peptide (Bitan et al., 2003; Chen et al., 2006). The most 
immediate interpretation of these results is that the exposure of cells to Aβ40 and Aβ42 peptides 
probably cause activation of T cells in a relatively short period of time, with consequent cell death, 
likely by apoptosis. These data are in line with the results of previous co-culture studies carried out 
to characterize the interaction between Aβ-presenting cells and some T cells-subpopulations, which 
showed that exposure of Th1 cells to Aβ40 and Aβ42 peptides cause cell death by apoptosis. It is no 
accident that stress conditions, e.g. due to the presence of toxic molecules, can induce a cell to 
initiate apoptosis. Often, cells in the diseased brain are more susceptible to enter apoptosis due to 
overexpression of cellular death receptors and sub-decoy-receptor expression, by binding with 
TRAIL (TNF-related apoptosis-inducing ligand). It has been demonstrated that together with other 
cytokines, the TRAIL is involved in some neurodegenerative diseases, including Alzheimer's 
disease (Hoffmann et al., 2009). 
By contrast, the effect of Aβ40 and Aβ42 peptides on the proliferation of T lymphocytes it is not yet 
clear. Previous studies on the reactivity of human T cells following exposure with Aβ peptide, 
showed a high proliferative index of T cells after treatment with the Aβ42 peptide, rather than with 
Aβ40 (Monsonego et al., 2003). This result is in conflict with our results and those of Trieb et al. 
and Ethell et al. Possibly, these discrepancies could be ascribed to the use of peptides with different 
purities, as well as to other differences in experimental models used (Miscia et al., 2009). Another 
possible interpretation is that other cofactors, closely associated with fibrils in vivo and perhaps lost 
during the purification procedures, may play a key role in activating T lymphocytes. Moreover, the 
mode of temporal activation of T cells could be related to the number of fibrils, and/or to the 
concentration of peptides.  
Further experiments should be carried out to assess whether and how these peptides are able to 
activate a non-specific inflammatory response, and if this is followed by apoptosis. Indeed, recent 
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studies have shown that use of drugs that interfere with the inflammatory response may represent a 
therapeutic approach to prevent and possibly slow down some forms of neurodegenerative disorders 
whose pathogenesis involves chronic inflammation. Therefore, a better understanding of factor(s) 
driving the neuroinflammation could help to develop novel strategies for treatment of these 
diseases. 
 
3.3.5 CONCLUSIONS 
 
Our preliminary studies carried out to evaluate the ability of AD peptides to act as superantigens 
have not given clear and unambiguous results. This could be dependent on several factors such as 
peptides concentrations, incubation times, cells used, co-factors absent in purified peptides. Further 
studies to specifically address these aspects are presently in progress in our laboratories. 
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